Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03759379 : HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Male or<br/>FemaleGender Male or
Female

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-85Age 18-85

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAmyloidosis

Trial Overview Read MoreRead more

This Phase III is evaluating the effectiveness of a targeted therapy (vutrisiran) in people with hereditary transthyretin amyloidosis.
 

This trial is treating patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Commercial Sponsor

Alnylam Pharmaceuticals

Summary

Vutrisiran (ALN-TTRSC02) : Participants will receive vutrisiran during the Treatment and Treatment Extension Periods. Drug: Vutrisiran (ALN-TTRSC02) : Patisiran will be administered by intravenous (IV) infusion.

Not Recruiting Hospitals Read MoreRead more

Closed

Box Hill Hospital, Malignant Haematology
Box Hill
Ms Liz Arnold
liz.arnold@monash.edu
03 9094 9516

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next